| Active Ingredient | SOMATROPIN |
| Therapeutic Class | SOMATROPHIN AGONIST |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | HYDROXYPROGESTERONE |
| Therapeutic Class | PROGESTINS |
| Indications | Amenorrhea, pre-term labour (prophylaxis). |
| Caution | Changes in appetite or weight, fluid retention, oedema, acne, chloasma (melasma), allergic skin rashes. |
| Dose Range |
Pre-term labour (prophylaxis): 250-500mg intramuscularly weekly during first half of pregnancy or longer. Amenorrhea: 375mg intramuscularly . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MEDROXYPROGESTERONE |
| Therapeutic Class | PROGESTINS |
| Indications |
Anovulatory dysfunctional uterin e bleeding (DUB), post menopausal hormone replacement therapy, contraception, carcinoma of the endometrium. |
| Caution | Fluid retention, menstrual disorders. Use with caution in conditions which worsen fluid retention. c.f. prescribing in liver disease p. 15. |
| Dose Range |
Oral: 2.5-10mg daily for at least 10 day s p er month as HRT; daily from day s 16 or 21 of cycle for 5-10 days in anovulatory DUB. Higher p arenteral doses are required in endometrical cancer. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | NORETHISTERONE |
| Therapeutic Class | PROGESTINS |
| Indications | See Medroxy progesterone Acetate. |
| Caution | c.f. prescribing in liver disease p. 15. Contraindicated in pregnancy . Ten times more potent than medroxy progesterone. |
| Dose Range |
Dysfunctional Uterine Bleeding: 1-2 tab. Daily for 6-12 days. To prevent relapse, 1-2 tab daily from 16th-25th day of cycle, combined with oestrogen if necessary . Endometriosis: 1 tab. Daily from 5th- 25th day of cycle for 6 mth or ½ tab. Daily , continu |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | THYROXINE |
| Therapeutic Class | THYROID AGENTS |
| Indications | Hypothyroidism. |
| Caution | Angina, sweating, headache, diarrhoea, tachycardia (features of thyrotoxicosis), weight loss, restlessness. |
| Dose Range |
50-100mcgs daily increased by 25-50mcg at intervals of about 4 weeks. Maintenance Dose: 100-200mcgs daily. Best taken on an empty stomach Start at low dose (12.5-50mcg daily ) in elderly or patients with ischaemic heart disease. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | CARBIMAZOLE |
| Therapeutic Class | ANTI-THYROID AGENTS |
| Indications | Hyperthyroidism. |
| Caution | Monitor carefully in pregnancy and breast feeding as overdose may cause fetal and neonatal thyroid depression. May cause skin rashes, joint swelling, arthalgias. |
| Dose Range |
Adult: 15- 40 mg (up to 60 mg) daily in divided doses until patient is euthyroid. Maintenance dose 5 to 15 mg daily , as a single dose. Pediatric: 0.75 mg/kg (max.30 mg) daily as single or divided doses. 12-18 y rs: 30mg daily initially , in single or div |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PROPYLTHIOURACIL |
| Therapeutic Class | ANTI-THYROID AGENTS |
| Indications | Hyperthyroidism. |
| Caution | Fever, leukopenia, rash. |
| Dose Range |
Adult: 200-400 mg daily (600-1200 mg in severe cases) in single or divided doses until euthyroid. Maintenance dose: 50-150 mg daily . Paediatric: neonates: 2.5-5 mg/kg twice daily ; 1 month to 1 yr: 2.5 mg/kg 3 times daily : 1- 18y rs: 25 -100mg 3 tim |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |